JP2023500032A5 - - Google Patents
Info
- Publication number
- JP2023500032A5 JP2023500032A5 JP2022521146A JP2022521146A JP2023500032A5 JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5 JP 2022521146 A JP2022521146 A JP 2022521146A JP 2022521146 A JP2022521146 A JP 2022521146A JP 2023500032 A5 JP2023500032 A5 JP 2023500032A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glp
- composition according
- receptor agonist
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024211204A JP2025027130A (ja) | 2019-11-06 | 2024-12-04 | 認知症におけるglp-1受容体作動薬 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501.8 | 2019-11-06 | ||
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| EP20186623.3 | 2020-07-20 | ||
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024211204A Division JP2025027130A (ja) | 2019-11-06 | 2024-12-04 | 認知症におけるglp-1受容体作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500032A JP2023500032A (ja) | 2023-01-04 |
| JP2023500032A5 true JP2023500032A5 (cg-RX-API-DMAC7.html) | 2023-11-14 |
| JP7670698B2 JP7670698B2 (ja) | 2025-04-30 |
Family
ID=73172681
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521146A Active JP7670698B2 (ja) | 2019-11-06 | 2020-11-05 | 認知症におけるglp-1受容体作動薬 |
| JP2024211204A Pending JP2025027130A (ja) | 2019-11-06 | 2024-12-04 | 認知症におけるglp-1受容体作動薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024211204A Pending JP2025027130A (ja) | 2019-11-06 | 2024-12-04 | 認知症におけるglp-1受容体作動薬 |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
| CN118510545A (zh) | 2021-12-02 | 2024-08-16 | 哥本哈根大学 | 用于治疗神经退行性疾病的肽-药物缀合物 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| WO2026096637A1 (en) * | 2024-10-30 | 2026-05-07 | Tiziana Life Sciences Plc | Glp-1 agonists and foralumab combination therapies |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| US8756102B2 (en) * | 2009-11-06 | 2014-06-17 | Edatanetworks Inc. | Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| AU2016379403B2 (en) * | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
-
2020
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
- 2020-11-06 TW TW114103408A patent/TWI923289B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2572768B2 (ja) | レボドパメチルエステルを有効成分とするパ−キンソン病治療剤 | |
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| TWI633887B (zh) | 用於預防及/或治療多囊性腎臟病之藥物 | |
| HRP20241052T1 (hr) | Semaglutid, namijenjen liječenju alzheimerove demencije | |
| JP2009514874A5 (cg-RX-API-DMAC7.html) | ||
| JP2024503265A5 (cg-RX-API-DMAC7.html) | ||
| EP1750677B1 (en) | Oral therapeutic compound delivery system | |
| JP2019531310A (ja) | 神経炎症と関連した病態を処置するためのデバイス及び方法 | |
| JP2019517542A5 (cg-RX-API-DMAC7.html) | ||
| WO2021185265A1 (zh) | 口服药物组合物 | |
| JP2021152060A (ja) | アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法 | |
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| JP2020522560A5 (cg-RX-API-DMAC7.html) | ||
| JP2019218379A5 (cg-RX-API-DMAC7.html) | ||
| ES2604254T3 (es) | Combinaciones de flurbiprofeno de liberación controlada y relajante muscular | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2019507786A5 (cg-RX-API-DMAC7.html) | ||
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| JP2007291070A (ja) | 催眠用医薬組成物 | |
| JP2019535830A5 (cg-RX-API-DMAC7.html) | ||
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| JP2021530568A5 (cg-RX-API-DMAC7.html) | ||
| RU2369393C2 (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна |